http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sumio Kaizaki,Dai Shirotani,Keiko Toya,Masako Iwamatsu,Yumiko Kato,Mikiko Maki,Takanori Hirami,Hiroshi Seki,Hiroyasu Nakata,Hisako Sato 한양대학교 세라믹연구소 2016 Journal of Ceramic Processing Research Vol.17 No.5
This paper concerns with the synthesis and the luminescence spectra of lanthanide complexes of Eu(III) and/or Eu(II) orTb(III) ions which are embedded into fibrous palygorskite and sepiolite clays in which the magnesium ion are ion exchangedwith lanthanide ions. The He-Cd laser excitation photoluminescence of the present complexes without organic ligands exhibitthe deferration effects. The phosphors with light harvesting ligands such as benzophenone derivatives and 1,10-phenanthrolinegive the fairly strong visible luminescence by UV-A light excitation with a LED black light in a light room under fluorescentlamps. Further, the temperature dependent phosphors with benzophenone derivatives exhibit the stronger luminescence withincreasing the temperature over 100 oC.
Naoya Murakami,Miho Watanabe,Takashi Uno,Shuhei Sekii,Kayoko Tsujino,Takahiro Kasamatsu,Yumiko Machitori,Tomomi Aoshika,Shingo Kato,Hisako Hirowatari,Yuko Kaneyasu,Tomio Nakagawa,Hitoshi Ikushima,Ken 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.3
Objective: The purposes of this trial were to demonstrate the feasibility and effectiveness of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients in the phase I/II prospective clinical trial. Methods: Patients with FIGO stage IB2-IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by magnetic resonance imaging were eligible for this clinical trial. The protocol therapy included 30–30.6 Gy in 15–17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of HBT and pelvic radiotherapy with a central shield up to 50–50.4 Gy in 25–28 fractions. The primary endpoint of phase II part was 2-year pelvic progression-free survival (PPFS) rate higher than historical control of 64%. Results: Between October 2015 and October 2019, 73 patients were enrolled in the initial registration and 52 patients proceeded to the secondary registration. With the median follow-up period of 37.3 months (range, 13.9–52.9 months), the 2- PPFS was 80.7% (90% confidence interval [CI]=69.7%–88%). Because the lower range of 90% CI of 2-year PPFS was 69.7%, which was higher than the historical control ICBT data of 64%, therefore, the primary endpoint of this study was met. Conclusion: The effectiveness of HBT were demonstrated by a prospective clinical study. Because the dose goal determined in the protocol was lower than 85 Gy, there is room in improvement for local control. A higher dose might have been needed for tumors with poor responses.